

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Currently Amended). A compound which is ~~crystalline~~ carvedilol dihydrogen phosphate hemihydrate.

2 (Original). The compound according to claim 1 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta as shown in Figure 1.

3 (Original). The compound according to claim 2 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about  $7.0 \pm 0.2$  (2θ),  $11.4 \pm 0.2$  (2θ),  $15.9 \pm 0.2$  (2θ),  $18.8 \pm 0.2$  (2θ),  $20.6 \pm 0.2$  (2θ),  $22.8 \pm 0.2$  (2θ), and  $25.4 \pm 0.2$  (2θ).

4 (Currently Amended). The compound according to claim 1 having an infrared spectrum which comprises characteristic absorption bands expressed in wave numbers as shown in Figure 6.

5 (Original). The compound according to claim 1 having a Raman spectrum which comprises characteristic peaks as shown in Figure 3.

6 (Original). A compound which is carvedilol dihydrogen phosphate dihydrate.

7 (Original). The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 9.

8 (Original). The compound according to claim 7 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about  $6.5 \pm 0.2$  (2θ),  $7.1 \pm 0.2$  (2θ),  $13.5 \pm 0.2$  (2θ),  $14.0 \pm 0.2$  (2θ),  $17.8 \pm 0.2$  (2θ),  $18.9 \pm 0.2$  (2θ), and  $21.0 \pm 0.2$  (2θ).

9 (Original). The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 25.

10 (Original). The compound according to claim 9 having characteristic peaks from  $0^\circ$  degrees 2-theta ( $2\theta$ ) to  $35^\circ$  degrees 2-theta ( $2\theta$ ) at about  $6.4 \pm 0.2$  ( $2\theta$ ),  $9.6 \pm 0.2$  ( $2\theta$ ),  $16.0 \pm 0.2$  ( $2\theta$ ),  $18.4 \pm 0.2$  ( $2\theta$ ),  $20.7 \pm 0.2$  ( $2\theta$ ), and  $24.5 \pm 0.2$  ( $2\theta$ ).

11 (Original). A compound which is carvedilol dihydrogen phosphate methanol solvate.

12 (Original). The compound according to claim 11 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 24.

13 (Original). The compound according to claim 12 having characteristic peaks from  $0^\circ$  degrees 2-theta ( $2\theta$ ) to  $35^\circ$  degrees 2-theta ( $2\theta$ ) at about  $6.9 \pm 0.2$  ( $2\theta$ ),  $7.2 \pm 0.2$  ( $2\theta$ ),  $13.5 \pm 0.2$  ( $2\theta$ ),  $14.1 \pm 0.2$  ( $2\theta$ ),  $17.8 \pm 0.2$  ( $2\theta$ ), and  $34.0 \pm 0.2$  ( $2\theta$ ).

14 (Original). A compound which is carvedilol dihydrogen phosphate.

15 (Original). The compound according to claim 14 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 28.

16 (Original). The compound according to claim 15 having characteristic peaks from  $0^\circ$  degrees 2-theta ( $2\theta$ ) to  $35^\circ$  degrees 2-theta ( $2\theta$ ) at about  $13.2 \pm 0.2$  ( $2\theta$ ),  $15.8 \pm 0.2$  ( $2\theta$ ),  $16.3 \pm 0.2$  ( $2\theta$ ),  $21.2 \pm 0.2$  ( $2\theta$ ),  $23.7 \pm 0.2$  ( $2\theta$ ), and  $26.0 \pm 0.2$  ( $2\theta$ ).

17 (Original). A compound which is carvedilol hydrogen phosphate.

18 (Original). The compound according to claim 17 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 29.

19 (Original). The compound according to claim 18 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 5.5 ± 0.2 (2θ), 12.3 ± 0.2 (2θ), 15.3 ± 0.2 (2θ), 19.5 ± 0.2 (2θ), 21.6 ± 0.2 (2θ), and 24.9 ± 0.2 (2θ).

20 (Original). A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

21 (Original). A pharmaceutical composition comprising the compound according to claim 6 and a pharmaceutically acceptable carrier.

22 (Original). A pharmaceutical composition comprising the compound according to claim 14 and a pharmaceutically acceptable carrier.

23 (Original). A pharmaceutical composition comprising the compound according to claim 17 and a pharmaceutically acceptable carrier.

24 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 1.

25 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 6.

26 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 14.

27(Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 17.

28 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 20.

29 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 21.

30 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 22.

31 (Original). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 23.